'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. [electronic resource]
Producer: 20130730Description: 1259-1265 p. digitalISSN:- 1465-2099
- Adult
- Aged
- Antiviral Agents -- therapeutic use
- Cohort Studies
- Female
- Genetic Predisposition to Disease
- Genotype
- Hepacivirus -- drug effects
- Hepatitis C -- drug therapy
- Humans
- Interferons -- therapeutic use
- Interleukins -- genetics
- Male
- Middle Aged
- Polymorphism, Single Nucleotide
- Prospective Studies
- Ribavirin -- therapeutic use
- United Kingdom
- Viral Load
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.